Literature DB >> 17991357

Contemporary progress in ovarian cancer screening.

Christine S Walsh1, B Y Karlan.   

Abstract

Our limited understanding of the natural biology of ovarian cancer, along with its low prevalence in the general population make early detection especially challenging. To be successful at the population level, an ovarian cancer screening test must prove its beneficial effect on ovarian cancer-specific mortality while achieving near-perfect specificity in order to minimize the harms resulting from false-positive results. No current screening tests for ovarian cancer fulfill these expectations. We review the current status and the challenges of ovarian cancer screening in the context of evidence-based principles that define a valuable cancer screening program.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991357     DOI: 10.1007/s11912-007-0068-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  50 in total

1.  The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

Authors:  J R van Nagell; P D DePriest; M B Reedy; H H Gallion; F R Ueland; E J Pavlik; R J Kryscio
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

2.  A new scoring system to differentiate benign from malignant adnexal masses.

Authors:  Juan Luis Alcázar; Luis T Mercé; Carmen Laparte; Matías Jurado; Guillermo López-García
Journal:  Am J Obstet Gynecol       Date:  2003-03       Impact factor: 8.661

3.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

Authors:  Eleftherios P Diamandis
Journal:  J Natl Cancer Inst       Date:  2004-03-03       Impact factor: 13.506

4.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

5.  Generating longitudinal screening algorithms using novel biomarkers for disease.

Authors:  Martin W McIntosh; Nicole Urban; Beth Karlan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-02       Impact factor: 4.254

6.  Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach.

Authors:  Akiko Horiuchi; Kazuko Itoh; Motohiko Shimizu; Ikuko Nakai; Teruyuki Yamazaki; Kaoru Kimura; Akihiko Suzuki; Isao Shiozawa; Noritane Ueda; Ikuo Konishi
Journal:  Gynecol Oncol       Date:  2003-03       Impact factor: 5.482

7.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

8.  Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound.

Authors:  M H Vuento; J P Pirhonen; J I Mäkinen; P J Laippala; M Grönroos; T A Salmi
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

9.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.

Authors:  Katherine R Kozak; Malaika W Amneus; Suzanne M Pusey; Feng Su; Mui N Luong; Sam A Luong; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

Review 10.  Progress and challenges in screening for early detection of ovarian cancer.

Authors:  Ian J Jacobs; Usha Menon
Journal:  Mol Cell Proteomics       Date:  2004-02-05       Impact factor: 5.911

View more
  2 in total

1.  Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.

Authors:  Archana Raamanathan; Glennon W Simmons; Nicolaos Christodoulides; Pierre N Floriano; Wieslaw B Furmaga; Spencer W Redding; Karen H Lu; Robert C Bast; John T McDevitt
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-09

2.  How close is the bench to the bedside? Metabolic profiling in cancer research.

Authors:  Que N Van; Timothy D Veenstra
Journal:  Genome Med       Date:  2009-01-20       Impact factor: 11.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.